Podcasts about resectability

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning discusses the robotic market. He explores the new FDA approval for the Johnson & Johnson robotic surgical system for clinical trials, the background of Johnson & Johnson MedTech, and the location for this trial. He also discusses the details of TAVR, what we currently know about TAVR, and highlights an article by Steve Bell that discusses his own views on Johnson & Johnson and the robotic market.    Joel also reviews recent JANS articles on The Society of Thoracic Surgeons expert consensus on the multidisciplinary management and resectability of locally advanced non-small cell lung cancer, a European multicenter study evaluating the prognosis of peripheral early-stage lung adenocarcinoma patients operated on by segmentectomy or lobectomy, early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis, and the use of hybrid stage I to stratify between single ventricle palliation and biventricular repair.   In addition, Joel explores an off-pump ASD closure with a two-layer patch attached to the right atrium, a repair of Scimitar syndrome in a two-year-old via VRAT, and robotic-assisted carinal reconstruction using cross table ventilation. Before closing, he highlights upcoming events in CT surgery.   JANS Items Mentioned  1.) The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer  2.) European Multicentre Study Evaluating the Prognosis of Peripheral Early-Stage Lung Adenocarcinoma Patients Operated on by Segmentectomy or Lobectomy  3.) Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED trial  4.) Use of Hybrid Stage I to Stratify Between Single Ventricle Palliation and Biventricular Repair  CTSNET Content Mentioned  1.) Off-Pump ASD Closure With a Two-Layer Patch Attached to the Right Atrium  2.) Repair of Scimitar Syndrome in a Two-Year-Old Via VRAT: Pitfalls of Intra-atrial Baffle  3.) Robotic-Assisted Carinal Reconstruction Using Cross Table Ventilation—A Novel Surgical Technique  Other Items Mentioned  Why am I so tough on Johnson & Johnson and Medtronic and their surgical robotic programs?  CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe clinical factors that should be considered when evaluating whether a patient with CSCC is a candidate for neoadjuvant immunotherapy; Review the clinical profiles of approved and emerging neoadjuvant immunotherapies for patients with resectable CSCC; and Outline practical considerations to optimize treatment outcomes for patients with resectable CSCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe clinical factors that should be considered when evaluating whether a patient with CSCC is a candidate for neoadjuvant immunotherapy; Review the clinical profiles of approved and emerging neoadjuvant immunotherapies for patients with resectable CSCC; and Outline practical considerations to optimize treatment outcomes for patients with resectable CSCC. This activity is intended for US healthcare professionals only.

CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/accurate-staging-and-determining-resectability-in-nsclc/24385/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

In this podcast, authors Dr Luca Bertolaccini and Dr Giulio Metro touch upon the need for a standard definition of resectability in patients with resectable stage III non-small cell lung cancer (NSCLC). This podcast gives the perspectives of a thoracic surgeon and an oncologist, and suggests a shared agreement between two of the main actors involved in the treatment of resectable stage III NSCLCs. This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00267-6.  All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, including the read out of overall survival data from the KEYNOTE-671 trial, definitions of resectability, and the incorporation of new guidance regarding multidisciplinary management.

In this episode, we explore the role of vascular surgeons in oncologic surgery. We will be discussing the nuances of vascular involvement in oncologic resection, common practices, and future directions of this collaborative surgical culture.   Dr. Adam Beck (@AWBeckMD) is a vascular surgeon and Professor of Surgery at the University of Alabama at Birmingham where he serves as the Director of the Division of Vascular Surgery and Endovascular Therapy, holds the Holt A. McDowell, Jr, MD Endowed Chair in Vascular Surgery and serves as the Director of Quality and Associate Chief Medical Quality Officer for the UAB Cardiovascular Institute. Dr. Beck completed his general surgery residency training and a surgical oncology research fellowship at the University of Texas-Southwestern Medical Center. He trained in vascular surgery at the Dartmouth-Hitchcock Medical Center and then completed a fellowship in advanced endovascular techniques, including branched and fenestrated endografts for aortic aneurysmal disease, at the University Medical Center of Groningen in The Netherlands. You can learn more about Dr. Adam Beck here.   Dr. Xavier Berard (@XavierBerardMD)  is a French vascular surgeon and serves as a Consultant in the Department of Vascular Surgery and Professor of Vascular and Endovascular Surgery in Bordeaux University Hospital in Bordeaux, France. He is board certified from the French College of Vascular and Endovascular Surgeons and from the European Society for Vascular and Endovascular Surgery. He has also completed a PhD in Vascular Biomaterials and has built a library of educational video content. He works closely with Institut Bergonié Bordeaux Cancer Center for sarcomas. You can see educational videos and learn more about Dr. Xavier Berard here   Dr. Sharif Ellozy (@SharifEllozy)  is a vascular surgeon at the New York-Presbyterian/Weill Cornell Medical Center where he serves as Associate Professor of Clinical Surgery in the Division of Vascular and Endovascular Surgery, and Program Director of the Vascular Surgery Fellowship program. He is also one of the founders of Audible Bleeding. He is readily involved in oncologic resection at the Memorial Sloan Kettering Cancer Center and works closely with surgical oncologists on operative cases that have vessel involvement.   Authors/Interviewers: Dr. Sree Kanna, MD - McGill, Montreal (@VulnerableAorta) Dr. Nakia Sarad, DO, MS - New York-Presbyterian/Queens - Weill Cornell, New York (@NakSaradDO)   Editors: Morgan Gold, MD,CM candidate - McGill, Montreal (@MorganSGold) Ezra Schwartz, MD,CM, MS, MMSc-Med Ed candidate - Harvard, Boston (@EzraSchwartz10)   Helpful Resources:   To learn more about sarcoma resections, check out the Schwarzbach papers on lower extremity sarcomas and retroperitoneal sarcomas   Click here to learn more about the NCCN Guidelines on Resectability of Pancreatic Cancers   Click here to learn more about IVC Reconstruction Techniques in Oncologic Surgery   Video of IVC Leiomyosarcoma Reconstructions here (courtesy of Dr. Berard)   Click here to learn more about the Renal Cell Carcinoma Mayo Staging System Click here to find the original article on the Shamblin Classification for Carotid Body Tumors   Check out this review paper on Oncovascular Surgery    Check out this paper on spiral endografts here Video of spiral saphenous vein graft technique here (courtesy of Dr. Berard)   What other topics would you like to hear about? Let us know more about you and what you think of our podcast through our Listener Survey or email us at AudibleBleeding@vascularsociety.org. Follow us on Twitter @audiblebleeding   Learn more about us at https://www.audiblebleeding.com/about-1/ and #jointheconversation.  

David A. Bluemke, MD, PhD, Editor of Radiology discusses four research articles from the November 2019 issue of Radiology. ARTICLES DISCUSSED – Summary of Opportunities in Interventional and Diagnostic Imaging by Using High-Performance Low-Field-Strength MRI. Radiology 2019; 293:384–393.; Summary of Statin Use and Knee Osteoarthritis Outcome Measures according to the Presence of Heberden Nodes: Results from the Osteoarthritis Initiative. Radiology 2019; 293:396–404.; Summary of Preoperative CT Classification of the Resectability of Pancreatic Cancer: Interobserver Agreement. Radiology 2019; 293:343–349.; Summary of Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology 2019; 293:424–433.;

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, discusses the factors that determine whether a person's pancreatic cancer is resectable and the importance of this factor in predicting clinical outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, discusses the factors that determine whether a person's pancreatic cancer is resectable and the importance of this factor in predicting clinical outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, discusses the factors that determine whether a person's pancreatic cancer is resectable and the importance of this factor in predicting clinical outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, discusses the factors that determine whether a person's pancreatic cancer is resectable and the importance of this factor in predicting clinical outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, discusses the factors that determine whether a person's pancreatic cancer is resectable and the importance of this factor in predicting clinical outcomes.

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, discusses the factors that determine whether a person's pancreatic cancer is resectable and the importance of this factor in predicting clinical outcomes.

Case-based discussion with multiple lung cancer experts on the optimal treatment of a patient with multi-station N2 node-positive squamous cell NSCLC, including whether surgery should be pursued.

Case-based discussion with multiple lung cancer experts on the optimal treatment of a patient with multi-station N2 node-positive squamous cell NSCLC, including whether surgery should be pursued.

This slide presentation by medical oncologist and lung cancer expert Dr. Jack West covers the most common management strategies for stage IIIA N2 node-positive NSCLC, with a particular focus on a comparison of preoperative treatment followed by surgery vs. chemo and radiation without surgery.